^ 2.02.12.2GRCh38: Ensembl release 89: ENSG00000069696、ENSG00000276825 - Ensembl, May 2017
^ 3.03.13.2GRCm38: Ensembl release 89: ENSMUSG00000025496 - Ensembl, May 2017
^Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
^Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
^Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. April 1991, 350 (6319): 610–4. PMID 1840645. doi:10.1038/350610a0.
^Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. August 2004, 24 (3): 165–205. PMID 15521361. doi:10.1081/RRS-200029981.
^Catalano M, Nobile M, Novelli E, Nöthen MM, Smeraldi E. Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol. Psychiatry. October 1993, 34 (7): 459–64. PMID 8268330. doi:10.1016/0006-3223(93)90236-7.
^Thapar A, Langley K, Owen MJ, O'Donovan MC. Advances in genetic findings on attention deficit hyperactivity disorder. Psychol Med. December 2007, 37 (12): 1681–92. PMID 17506925. doi:10.1017/S0033291707000773.
^Gene Overview of All Published Schizophrenia-Association Studies for DRD4 (页面存档备份,存于互联网档案馆) - SzGene database at Schizophrenia Research Forum.
^Munafò MR, Yalcin B, Willis-Owen SA, Flint J. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data. Biol. Psychiatry. January 2008, 63 (2): 197–206. PMID 17574217. doi:10.1016/j.biopsych.2007.04.006.
^ 12.012.1Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL, Ryder OA, Spence MA, Swanson JM, Moyzis RK. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am. J. Hum. Genet. May 2004, 74 (5): 931–44. PMC 1181986. PMID 15077199. doi:10.1086/420854.
^Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem. September 1995, 65 (3): 1157–1165. PMID 7643093. doi:10.1046/j.1471-4159.1995.65031157.x.
^Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. American Journal of Psychiatry. July 2001, 158 (7): 1052–7 [2013-02-15]. PMID 11431226. doi:10.1176/appi.ajp.158.7.1052. (原始内容存档于2011-06-12).
^Chen CS, Burton M, Greenberger E, Dmitrieva J. Population migration and the variation of dopamine D4 receptor (DRD4) allele frequencies around the globe. Evolution and Human Behavior. September 1999, 20 (5): 309–324. doi:10.1016/S1090-5138(99)00015-X.
^Eisenberg DT, Campbell B, Gray PB, Sorenson MD. Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern Kenya. BMC Evol. Biol. 2008, 8: 173. PMC 2440754. PMID 18544160. doi:10.1186/1471-2148-8-173.
^Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat. Genet. January 1996, 12 (1): 78–80. PMID 8528256. doi:10.1038/ng0196-78.
^Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat. Genet. January 1996, 12 (1): 81–4. PMID 8528258. doi:10.1038/ng0196-81.
^Munafo MR, Yalcin B, Willis-Owen SA, Flint J. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data. Biol Psychiatry. 2008, 63 (2): 197–206. PMID 17574217. doi:10.1016/j.biopsych.2007.04.006.
^ 20.020.120.220.3Posner MI, Rothbart MK, Sheese BE, Voelker P. Control networks and neuromodulators of early development. Dev Psychol. May 2012, 48 (3): 827–35. PMID 21942663. doi:10.1037/a0025530.
^Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl.). 2006, 188 (2): 244–51. PMID 16915381. doi:10.1007/s00213-006-0490-4.
^Moreland RB, Patel M, Hsieh GC, Wetter JM, Marsh K, Brioni JD. A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol. Biochem. Behav. 2005, 82 (1): 140–7. PMID 16153699. doi:10.1016/j.pbb.2005.08.001.
^Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO. Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. Journal of Medicinal Chemistry. July 2004, 47 (15): 3853–64. PMID 15239663. doi:10.1021/jm030505a.
^Patel MV, Kolasa T, Mortell K; et al. Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J. Med. Chem. December 2006, 49 (25): 7450–65. PMID 17149874. doi:10.1021/jm060662k. 引文格式1维护:显式使用等标签 (link)
^ 25.025.1Hübner H, Kraxner J, Gmeiner P. Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments. J. Med. Chem. 2000, 43 (23): 4563–9. PMID 11087581. doi:10.1021/jm0009989.
^Kolasa T, Matulenko MA, Hakeem AA; et al. 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. J. Med. Chem. August 2006, 49 (17): 5093–109. PMID 16913699. doi:10.1021/jm060279f. 引文格式1维护:显式使用等标签 (link)
^Enguehard-Gueiffier C, Hübner H, El Hakmaoui A; et al. 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J. Med. Chem. June 2006, 49 (13): 3938–47. PMID 16789750. doi:10.1021/jm060166w. 引文格式1维护:显式使用等标签 (link)
^Nakane M, Cowart MD, Hsieh GC; et al. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology. July 2005, 49 (1): 112–21. PMID 15992586. doi:10.1016/j.neuropharm.2005.02.004. 引文格式1维护:显式使用等标签 (link)
^ 29.029.1Prante O, Tietze R, Hocke C, Löber S, Hübner H, Kuwert T, Gmeiner P. Synthesis, Radiofluorination, and In Vitro Evaluation of Pyrazolo[1,5-a]pyridine-Based Dopamine D4 Receptor Ligands: Discovery of an Inverse Agonist Radioligand for PET. J. Med. Chem. 2008, 51 (6): 1800–10. PMID 18307287. doi:10.1021/jm701375u.
^Kulagowski JJ, Broughton HB, Curtis NR; et al. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J. Med. Chem. May 1996, 39 (10): 1941–2. PMID 8642550. doi:10.1021/jm9600712. 引文格式1维护:显式使用等标签 (link)
^Patel S, Freedman S, Chapman KL; et al. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J. Pharmacol. Exp. Ther. 1 November 1997, 283 (2): 636–47. PMID 9353380. 引文格式1维护:显式使用等标签 (link)
^Patel S, Patel S, Marwood R; et al. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol. Pharmacol. December 1996, 50 (6): 1658–64. PMID 8967990. 引文格式1维护:显式使用等标签 (link)
^Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. J. Pharmacol. Exp. Ther. 1 October 1998, 287 (1): 167–86 [2013-02-15]. PMID 9765336. (原始内容存档于2003-07-12).
^Lanig H, Utz W, Gmeiner P. Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J. Med. Chem. 2001, 44 (8): 1151–7. PMID 11312915. doi:10.1021/jm001055e.
外部链接
Dopamine Receptors: D4. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. (原始内容存档于2012-03-05).